This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/513741-sanofi-manufacture-pfizer-covid19-vaccine/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 1 | Version 2 |
|---|---|
| French pharma giant Sanofi agrees to make vaccines from rivals Pfizer-BioNTech | French pharma giant Sanofi agrees to make vaccines from rivals Pfizer-BioNTech |
| (about 2 months later) | |
| French pharma giant Sanofi has bowed to pressure from the French government and vowed to produce over 125 million doses of rivals Pfizer and BioNTech’s Covid-19 vaccine in an extraordinary development in the pharma industry. | French pharma giant Sanofi has bowed to pressure from the French government and vowed to produce over 125 million doses of rivals Pfizer and BioNTech’s Covid-19 vaccine in an extraordinary development in the pharma industry. |
| Amid a slew of delays and a weak trial showing in December – which cited the need to improve efficacy among older recipients – Sanofi and GlaxoSmithKline will begin phase 2 trials of their own Covid-19 vaccine next month, but do not expect to reach regulatory approval and production phases until the end of 2021. | Amid a slew of delays and a weak trial showing in December – which cited the need to improve efficacy among older recipients – Sanofi and GlaxoSmithKline will begin phase 2 trials of their own Covid-19 vaccine next month, but do not expect to reach regulatory approval and production phases until the end of 2021. |
| CEO Paul Hudson has announced that “in order to be helpful as of now,” his company has decided to lend a hand to the global vaccination effort. In order to do this, Sanofi facilities in Frankfurt will begin production of the Pfizer-BioNTech vaccine by August 2021. | CEO Paul Hudson has announced that “in order to be helpful as of now,” his company has decided to lend a hand to the global vaccination effort. In order to do this, Sanofi facilities in Frankfurt will begin production of the Pfizer-BioNTech vaccine by August 2021. |
| The total monetary value of the deal has not yet been disclosed publicly. | The total monetary value of the deal has not yet been disclosed publicly. |
| Sanofi faced pressure from the French government to use its facilities to produce vaccines, despite them belonging to their rivals. A combination of extraordinarily high demand and supply and distribution issues with the ongoing vaccine rollout spurred the decision to acquiesce to the demands. | Sanofi faced pressure from the French government to use its facilities to produce vaccines, despite them belonging to their rivals. A combination of extraordinarily high demand and supply and distribution issues with the ongoing vaccine rollout spurred the decision to acquiesce to the demands. |
| “While our utmost priority remains to advance our two Covid-19 vaccine programs, we recognize that some companies are facing challenges with their production,” a Sanofi spokesperson said. | “While our utmost priority remains to advance our two Covid-19 vaccine programs, we recognize that some companies are facing challenges with their production,” a Sanofi spokesperson said. |
| “Therefore, where we have the right manufacturing capabilities, without compromising other essential medicines and vaccines, and where we believe we can make a difference, we are stepping forward to do more for the fight against Covid and show solidarity across the industry.” | “Therefore, where we have the right manufacturing capabilities, without compromising other essential medicines and vaccines, and where we believe we can make a difference, we are stepping forward to do more for the fight against Covid and show solidarity across the industry.” |
| Pfizer and BioNTech are reportedly targeting production of two billion doses of coronavirus vaccine by the close of 2021. | Pfizer and BioNTech are reportedly targeting production of two billion doses of coronavirus vaccine by the close of 2021. |
| Meanwhile, AstraZeneca, another vaccine producer, has suffered manufacturing delays that will significantly impact its first-quarter deliveries to Europe. | Meanwhile, AstraZeneca, another vaccine producer, has suffered manufacturing delays that will significantly impact its first-quarter deliveries to Europe. |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |